All In Biotech

Drug Trial Radar · NCT04338061

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (evolutionRMS 2)

Last checked: Nov 20, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,166 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,166

Actual

Start

Jul 2, 2020

Primary completion

Oct 2, 2023

Study completion Mar 19, 2024

Sponsor

Sponsor type
Industry
Collaborators
EMD Serono Research & Development Institute, Inc.
First posted
Apr 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • TeriflunomideDrug

    Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period.

  • EvobrutinibDrug

    Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)Time frame: Baseline up to 170 weeks

Locations

278 sites in 32 countries. Site status is shown where the registry gives one.

  • Research Site 752

    Cullman, Alabama

  • Research Site 741

    Scottsdale, Arizona

  • Research Site 704

    Tucson, Arizona

  • Research Site 751

    Hanford, California

  • Research Site 737

    West Hollywood, California

  • Research Site 759

    Colorado Springs, Colorado

  • Research Site 725

    Fort Collins, Colorado

  • Research Site 746

    Altamonte Springs, Florida

  • Research Site 718

    Jacksonville, Florida

  • Research Site 702

    Naples, Florida

  • Research Site 740

    Orlando, Florida

  • Research Site 726

    Port Charlotte, Florida

  • Research Site 719

    Sarasota, Florida

  • Research Site 743

    Tampa, Florida

  • Research Site 707

    Tampa, Florida

  • Research Site 732

    Vero Beach, Florida

  • Research Site 705

    Weeki Wachee, Florida

  • Research Site 753

    West Palm Beach, Florida

  • Research Site 742

    Honolulu, Hawaii

  • Research Site 715

    Evanston, Illinois

  • Research Site 714

    Fort Wayne, Indiana

  • Research Site 744

    Lafayette, Indiana

  • Research Site 717

    Overland Park, Kansas

  • Research Site 735

    Nicholasville, Kentucky

  • Research Site 706

    Scarborough, Maine

  • Research Site 738

    Detroit, Michigan

  • Research Site 723

    St Louis, Missouri

  • Research Site 724

    Amherst, New York

  • Research Site 736

    Asheville, North Carolina

  • Research Site 712

    Chapel Hill, North Carolina

  • Research Site 730

    Raleigh, North Carolina

  • Research Site 728

    Winston-Salem, North Carolina

  • Research Site 711

    Canton, Ohio

  • Research Site 757

    Columbus, Ohio

  • Research Site 734

    Dayton, Ohio

  • Research Site 748

    Philadelphia, Pennsylvania

  • Research Site 703

    San Antonio, Texas

  • Research Site 721

    Norfolk, Virginia

  • Research Site 143

    Grodno, Belarus

  • Research Site 144

    Homyel, Belarus

Showing 40 of 278 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.